Standard blood work alone cannot reliably detect bone cancer in dogs. There are no blood tests that definitively diagnose osteosarcoma, the most common type of canine bone cancer. However, certain blood markers can raise suspicion, help assess overall health, and offer clues about prognosis once a diagnosis is made. The actual diagnosis still depends on imaging and tissue sampling.
What Blood Work Can and Cannot Tell You
A routine blood panel, which includes a complete blood count and chemistry profile, was not designed to catch bone cancer. These tests measure organ function, blood cell counts, and enzyme levels. They can reveal that something is off in the body, but they cannot pinpoint a bone tumor. Even veterinary oncology guidelines acknowledge there is a lack of reliable blood-based biomarkers for osteosarcoma in clinical practice.
That said, blood work is almost always part of the workup when bone cancer is suspected. It helps your vet assess whether the liver, kidneys, and other organs are functioning well, which matters for treatment planning. It can also flag indirect signs that something abnormal is happening in the bones.
Alkaline Phosphatase: The Most Watched Marker
The single most discussed blood value in canine bone cancer is alkaline phosphatase, or ALP. This enzyme exists in several forms throughout the body, including one produced specifically by bone-building cells called osteoblasts. When osteosarcoma develops, it can drive abnormal bone activity, releasing more of this enzyme into the bloodstream. Dogs with bone cancer sometimes show ALP levels well above the normal reference range, which varies by lab but generally falls between about 20 and 289 U/L.
Here’s the problem: elevated ALP is not specific to bone cancer. Young, growing dogs naturally have ALP levels two to ten times higher than adults because their bones are still developing. Dogs with healing fractures can see ALP spike to around 360 U/L. Cushing’s disease, steroid medications, liver disease, and even chronic stress can push ALP up through different pathways. In dogs specifically, a unique corticosteroid-induced form of ALP exists that no other species has, making elevated readings even harder to interpret.
So while a high ALP level in a limping large-breed dog raises a red flag, it doesn’t confirm cancer. And a normal ALP level doesn’t rule it out. Some dogs with confirmed osteosarcoma have ALP values well within the normal range.
ALP as a Prognostic Tool After Diagnosis
Where ALP becomes genuinely useful is after bone cancer has already been confirmed. Dogs with normal pre-treatment ALP levels consistently survive significantly longer than dogs with elevated levels. Elevated ALP is thought to correlate with a greater tumor burden or the presence of micrometastatic disease, meaning cancer cells that have already spread to other sites but aren’t yet visible on imaging.
The relationship is dose-dependent. Research on osteosarcoma in flat and irregular bones found that for every 100% increase in ALP above normal, the risk of death increased by a factor of 1.7. This makes ALP one of the few blood-based measurements that veterinary oncologists use to help predict outcomes and guide treatment conversations.
Calcium and Other Blood Abnormalities
Elevated blood calcium, known as hypercalcemia, is another finding that sometimes appears alongside cancer in dogs. Malignancy is actually the most common pathologic cause of elevated ionized calcium in dogs. However, bone tumors specifically account for a small slice of cancer-related hypercalcemia cases, roughly 7% in one large study. Most malignancy-associated hypercalcemia comes from lymphoma and other cancers that release hormones affecting calcium regulation.
When hypercalcemia does occur with bone cancer, it happens because the tumor breaks down surrounding bone tissue, releasing calcium into the blood. Moderate to severe elevations are more strongly linked to malignancy than mild ones. Still, this finding is uncommon enough in osteosarcoma that normal calcium levels tell you very little either way.
Some dogs with osteosarcoma also show changes in their white blood cell counts. Higher numbers of circulating monocytes and lymphocytes before treatment have been associated with shorter disease-free intervals after surgery and chemotherapy. Dogs with bone cancer also tend to have an altered inflammatory profile compared to healthy dogs. These shifts are subtle and overlap with many other conditions, so they don’t serve as diagnostic flags on their own.
How Bone Cancer Is Actually Diagnosed
The diagnostic path for canine bone cancer relies on imaging first. X-rays are typically the starting point, and osteosarcoma often has a characteristic appearance: aggressive bone destruction mixed with new bone formation, usually centered around the end of a long bone in a large or giant breed dog. The combination of a classic X-ray pattern, the right signalment (large breed, middle-aged or older), and the right location (near the wrist or shoulder) can give a vet strong suspicion.
Confirmation requires a tissue sample. This can be a fine needle aspirate, where a needle is inserted into the lesion to collect cells, or a core biopsy that retrieves a small cylinder of bone tissue for examination under a microscope. In some cases, advanced imaging like MRI is used to guide the biopsy, particularly for tumors in hard-to-reach locations like the spine.
Chest X-rays or CT scans are also standard to check for visible lung metastasis, since osteosarcoma spreads to the lungs in the vast majority of cases over time. Blood work fits into this staging process as a health assessment and prognostic tool, not as a cancer detector.
Why a Definitive Blood Test Doesn’t Exist Yet
Researchers have been searching for reliable blood-based biomarkers for canine osteosarcoma for years without a breakthrough. The challenge is that bone cancer doesn’t produce a unique, easily measurable substance that distinguishes it from other bone diseases, liver conditions, or normal variation. ALP of bone origin correlates with osteoblastic activity, but it cannot differentiate osteosarcoma from other bone-forming tumors or even reactive bone lesions like infections.
Dogs also respond to osteosarcoma very differently from one another. Some develop detectable metastasis quickly after treatment while others survive much longer, yet current blood markers can’t reliably sort patients into these groups ahead of time. This variability makes it difficult to identify a single blood value that works as a screening tool across the board.
For now, if your dog is showing signs like persistent lameness, swelling near a joint, or a sudden fracture without major trauma, blood work will be part of the evaluation. Just know that normal results don’t mean cancer is off the table, and abnormal results don’t confirm it. The real answers come from imaging and biopsy.